Fluoroquinolones and the Risk of Serious Arrhythmia: A Population-Based Study
Open Access
- 3 August 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 55 (11) , 1457-1465
Abstract
Background. Fluoroquinolones have been suspected to cause cardiac arrhythmia but data are lacking, particularly for the individual fluoroquinolones. We assessed the risk of serious arrhythmia, defined as ventricular arrhythmia or sudden/unattended death identified in hospital discharge diagnoses, related to fluoroquinolones as a class as well as for each individual molecule. Methods. We used a cohort of patients treated for respiratory conditions from 1 January 1990 to 31 December 2005, identified using the healthcare databases from the province of Quebec (Canada), with follow-up until 31 March 2007. A nested case-control analysis was performed within this cohort, with all cases of serious arrhythmia occurring during follow-up identified from hospitalization records. These cases were matched with up to 20 controls. Conditional logistic regression was used to compute adjusted rate ratios (RRs) of serious arrhythmia associated with fluoroquinolone use. Results. Within the cohort of 605 127 subjects, 1838 cases were identified (incidence rate = 4.7/10 000 person-years). The rate of serious arrhythmia was elevated with current fluoroquinolone use (RR = 1.76; 95% confidence interval [CI], 1.19–2.59), in particular with new current use (RR = 2.23; 95% CI, 1.31–3.80). Gatifloxacin use was associated with the highest rate (RR = 7.38; 95% CI, 2.30–23.70); moxifloxacin and ciprofloxacin were also associated with elevated rates of serious arrhythmia (RR = 3.30; 95% CI, 1.47–7.37 and RR = 2.15; 95% CI, 1.34–3.46, respectively). Conclusions. The use fluoroquinolones is associated with an elevated risk of serious arrhythmia, with some differences among molecules. Given that the individual fluoroquinolones share various indications, the relative risks of serious arrhythmia could inform the choice of different molecules in high-risk patients.Keywords
This publication has 36 references indexed in Scilit:
- Azithromycin and the Risk of Cardiovascular DeathNew England Journal of Medicine, 2012
- A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de PointesCirculation: Cardiovascular Genetics, 2012
- Identification of a Kir3.4 Mutation in Congenital Long QT SyndromeThe American Journal of Human Genetics, 2010
- Safety Profile of the FluoroquinolonesDrug Safety, 2010
- Antimicrobials and the Risk of Torsades de PointesDrug Safety, 2010
- Validation of diagnostic codes for outpatient‐originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims dataPharmacoepidemiology and Drug Safety, 2009
- Effect of Macrolide and Fluoroquinolone Antibacterials on the Risk of Ventricular Arrhythmia and Cardiac ArrestDrug Safety, 2009
- The effect of publication on Internet-based solicitation of personal-injury litigantsCanadian Medical Association Journal, 2007
- Assessment of pharmacokinetic–pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniaeDiagnostic Microbiology and Infectious Disease, 2005
- Profiles of Hepatic and Dysrhythmic Cardiovascular Events Following Use of Fluoroquinolone AntibacterialsDrug Safety, 2001